Prognosis and Clinicopathology of CXCR4 in Colorectal Cancer Patients: a Meta-analysis

The chemokine receptor 4 (CXCR4) has been widely used in diagnosis and prognosis of colorectal cancer(CRC). However, there is no current consensus on the impact of CXCR4 on CRC patients. The purpose of thisstudy was to evaluate the prognostic and clinicopathological importance of CXCR4 in CRC patients. Databases,such as PubMed, Cochrane library, CBM and EMBASE updated to 2014 were searched to include eligible articles.We analysed correlations between CXCR4 expression and clinicopathological features and overall survival(OS). A total of 1, 055 CRC patients from twelve studies were included in the study. The pooled odds ratios(ORs) which indicated CXCR4 expression was likely to be associated with TNM stage (OR=0.43, CI=0.34-0.55,P<0.00001), lymph node status (OR=2.23, CI=1.23-4.05, P=0.008) and vascular invasion (OR=2.21, CI=1.11-4.39,P=0.02). Poor overall survival of CRC cancer was found to be significantly related to CXCR4 overexpression(hazard ratio (HR) 1.36 CI=1.17-1.59, P<0.0001), whereas combined ORs revealed that CXCR4 expression hadno correlation with gender or differentiation. Based on the published studies, CXCR4 overexpression in patientsw ith CRC indicates poor survival outcome and clinicopathological factors.